No Benefit Offered By Bevacizumab For Newly Diagnosed Glioblastoma

Jun 4, 2013 | Posted by: roboblogger | Full story: MediLexicon

The angiogenesis inhibitor bevacizumab failed to increase overall survival or statistically significant progression-free survival for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

Comments
1 - 2 of 2 Comments Last updated Wednesday Jul 16

Since: Dec 05

Reading, PA

|
Report Abuse
|
Judge it!
|
#1
Jun 4, 2013
 
Avastin fails to prolong life in glioblastoma brain cancer patients?

Wow! This is blockbuster news! In one study, patients who were expected to benefit the most from Avastin based on "genetic" testing had the worst survival rates.

Bevacizumab-induced tumor calcifications can be elicited in glioblastoma microspheroid culture and represent massive calcium accumulation death (MCAD) of tumor endothelial cells

http://precedings.nature.com/documents/7069/v...

Since: Dec 05

Reading, PA

|
Report Abuse
|
Judge it!
|
#2
Wednesday Jul 16
 
MCED explains why glioblastoma (the most common primary brain tumor) patients who have favorable responses to bevacizumab (Avastin) develop early calcifications in the tumor bed while glioblastoma patients with poor responses to bevacizumab do not develop calcifications.

http://www.vasocell.com/MCED_Home.html

MCED Discovery

http://www.vasocell.com/MCED_Discovery.html

Tell me when this thread is updated: (Registration is not required)

Add to my Tracker Send me an email

Type in your comments below
Name
(appears on your post)
Comments
Characters left: 4000
Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

•••
•••